BofA raised the firm’s price target on Axsome Therapeutics (AXSM) to $176 from $173 and keeps a Buy rating on the shares after a revenue beat in Q2 on better-than-expected Auvelity and Sunosi performance. The firm sees the peak sales opportunity for Auvelity across multiple indications being “underappreciated,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Reports Strong Q2 2025 Growth
- Axsome Therapeutics: Strong Sales Performance and Strategic Growth Initiatives Drive Buy Rating
- Optimistic Outlook for Axsome Therapeutics: Strong Financial Performance and Growth Potential Justify Buy Rating
- Strong Growth Prospects and Strategic Advancements Propel Axsome Therapeutics to ‘Buy’ Rating
- Morning Movers: Wayfair surges following second quarter results